A Pilot Study to Identify Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors
Phase of Trial: Phase IV
Latest Information Update: 28 Sep 2017
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 01 Jun 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 01 Jun 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 08 Feb 2016 Planned End Date changed from 1 May 2016 to 1 May 2017 as reported by ClinicalTrials.gov record.